Therefore, not surprisingly, it has been suggested that targeting pluripotency transcription factors such as Nanog and SOX2 can be a promising strategy to solve the current therapeutic limitation on hard-to-treat cancer types such as GBM28. The gene discussed is NANOG; the disease is cancer.